Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib

被引：4

作者：

Doi, Ayako ^{[1
]}

Kuboki, Yasutoshi ^{[1
,2
]}

Shitara, Kohei ^{[1
]}

Fukuoka, Shota ^{[1
]}

Bando, Hideaki ^{[1
]}

Okamoto, Wataru ^{[1
]}

Kojima, Takashi ^{[1
]}

Doi, Toshihiko ^{[2
]}

Ohtsu, Atsushi ^{[3
]}

Yoshino, Takayuki ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwanoha 6-5-1, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

CLINICAL COLORECTAL CANCER | 2017年 / 16卷 / 02期

关键词：

Chemotherapy; GI perforation mCRC; Regorafenib; VEGF; ENDOTHELIAL GROWTH-FACTOR; PHASE-3; TRIAL; TUMOR ANGIOGENESIS; DOUBLE-BLIND; BEVACIZUMAB; PLACEBO; FLUOROURACIL; MULTICENTER; COMBINATION; LEUCOVORIN;

D O I：

10.1016/j.clcc.2016.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Regorafenib is an oral multikinase inhibitor that targets multiple pathways, including vascular endothelial growth factor receptor, and improves the survival of patients with metastatic colorectal cancer (mCRC). Gastrointestinal (GI) perforation and fistula are well-recognized adverse events associated with agents that target the VEGF pathway, including bevacizumab. We report 5 cases of GI perforation or fistula formation during treatment with regorafenib. We identified 1 case of GI perforation (0.6%) and 4 cases of fistula formation (2.4%) among 170 patients with mCRC administered regorafenib in our hospital. In all 5 cases, GI perforation or fistula involved the residual tumor and were successfully treated with antibiotic therapy or surgery and recovered from these adverse events. It is important to recognize that GI perforation and fistula can occur in patients treated with regorafenib. (C) 2016 The Author(s). Published by Elsevier Inc.

引用

页码：E109 / E113

页数：5

共 28 条

[11] Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma [J].

Inoue, Takaaki ;

Kinoshita, Hidefumi ;

Komai, Yoshihiro ;

Kawabata, Takashi ;

Kawa, Gen ;

Uemura, Yoshiko ;

Matsuda, Tadashi .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10

[12] Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study [J].

Kabbinavar, Fairooz F. ;

Flynn, Patrick J. ;

Kozloff, Mark ;

Ashby, Mark A. ;

Sing, Amy ;

Barr, Charles E. ;

Grothey, Axel .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (08) :1126-1132

[13] Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study [J].

Kozloff, Mark ;

Yood, Marianne Ulcickas ;

Berlin, Jordan ;

Flynn, Patrick J. ;

Kabbinavar, Fairooz F. ;

Purdie, David M. ;

Ashby, Mark A. ;

Dong, Wei ;

Sugrue, Mary M. ;

Grothey, Axel .

ONCOLOGIST, 2009, 14 (09) :862-870

[14] Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Li, Jin ;

Qin, Shukui ;

Xu, Ruihua ;

Yau, Thomas C. C. ;

Ma, Brigette ;

Pan, Hongming ;

Xu, Jianming ;

Bai, Yuxian ;

Chi, Yihebali ;

Wang, Liwei ;

Yeh, Kun-Huei ;

Bi, Feng ;

Cheng, Ying ;

Le, Anh Tuan ;

Lin, Jen-Kou ;

Liu, Tianshu ;

Ma, Dong ;

Kappeler, Christian ;

Kalmus, Joachim ;

Kim, Tae Won .

LANCET ONCOLOGY, 2015, 16 (06) :619-629

[15] Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups [J].

Qi, Wei-Xiang ;

Shen, Zan ;

Tang, Li-Na ;

Yao, Yang .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) :893-906

[16] Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis [J].

Qi, Wei-Xiang ;

Sun, Yuan-Jue ;

Tang, Li-Na ;

Shen, Zan ;

Yao, Yang .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (03) :394-403

[17] Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic [J].

Ranieri, Girolamo ;

Patruno, Rosa ;

Ruggieri, Eustachio ;

Montemurro, Severino ;

Valerio, Paolo ;

Ribatti, Domenico .

CURRENT MEDICINAL CHEMISTRY, 2006, 13 (16) :1845-1857

[18] Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists [J].

Rey, Jean-Baptiste ;

Launay-Vacher, Vincent ;

Tournigand, Christophe .

TARGETED ONCOLOGY, 2015, 10 (02) :199-213

[19] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study [J].

Saltz, Leonard B. ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Cassidy, Jim .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2013-2019

[20]

Santos-Rancaño R, 2013, REV ESP ENFERM DIG, V105, P370, DOI 10.4321/s1130-01082013000600014

← 1 2 3 →